ArticleBJUI compass2026
GLP-1RA use improves outcomes post partial nephrectomy in T2DM patients with RCC: A TriNetX study.
Article in BJUI compass, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- GLP-1RA use improves outcomes post partial nephrectomy in T2DM patients with RCC: A TriNetX study.BJUI compass · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The purpose of this study is to investigate the impact of Glucagon-like peptide-1 receptor agonists (GLP-1RAs) use on 90-day postoperative outcomes and overall survival following partial nephrectomy (PN) for renal cell carcinoma (RCC), where type 2 diabetes mellitus (T2DM) is a common comorbidity. Materials and Methods: The TriNetX database was used to retrospectively identify T2DM patients who underwent PN. Patients prescribed GLP-1RAs were identified and matched in a 1:1 ratio with control patients who were not prescribed GLP-1RAs based on baseline characteristics, comorbidities, metformin and insulin prescription, and renal function laboratory values. For 90-day postoperative adverse events, risk difference, risk ratio and odds ratio with 95% confidence intervals were calculated. Kaplan-Meier analysis, log-rank tests and multivariable Cox Proportional Hazards model were performed to measure the effect of GLP-1RAs use on overall survival. Results: Use of GLP-1RAs was associated with lower odds of acute kidney injury (odds ratio [OR] = 0.712), arrhythmia (OR = 0.725), readmission (OR = 0.8) and ileus (OR = 0.336) compared to the non-GLP-1RAs group ( Conclusion: Use of GLP-1RAs was associated with reduced incidence of 90-day postoperative complications, such as acute kidney injury, arrhythmia, readmission and ileus, potentially contributing to improved overall survival. These results align with ongoing studies investigating the broader benefits of the use of GLP-1RAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.